Louisiana Patients Could Lose Access to GLP-1 Weight-Loss Drugs as Coverage Vanishes Highlights Louisiana state employees are already prohibited from using GLP-1s for weight loss despite $200 million annual spending on diabetes coverage Over 41 million Americans lost commercial insurance coverage for Wegovy in 2026, with major insurers eliminating coverage nationwide Four states, including California and Pennsylvania, eliminated Medicaid coverage for obesity treatment between October 2025 and January 2026 Louisiana Medicaid provides limited coverage for one non-GLP-1 weight-loss drug but restrictions remain tight Patients face monthly costs ranging from $936 to $1,349 without insurance coverage BATON ROUGE, La
At some point we will see that plateau as more consumers try it. At Medica, every client employer group covers GLP-1 medications for FDA-approved diabetes indications
Query must be non-leading and offer multiple-choice options per AHIMA query practice guidelines
The various techniques for cell lysis or disruption include enzymatic, chemical, and mechanical means, each with its unique advantages and disadvantages (Grigorov et al
By contrast, compounded semaglutide may vary in quality from one batch to the next, depending on the compounding pharmacys standards and procedures
